RxDoctor Payments Data

Steven Lamm, MD

Internal Medicine · New York, NYNPI 1992856702

Payments from drug & device makers

$5,618in general payments, 2019–2025

Across 249 payments — averaging $22.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$4K
  • Inspiremd Ltd$879
  • Alkermes, Inc.$230
  • Gilead$198
  • Lilly USA, LLC$151
  • Astellas Pharma US Inc$99
  • plus $402 from 12 others

What the payments were for

  • Consulting fees$1,39525%
  • Food & beverage$4,14574%
  • Education$791%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,618 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$158,014
Medicare patients
578
Services billed
6,356

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide248$278,579
OzempicSemaglutide241$263,107
EliquisApixaban65$71,746
JardianceEmpagliflozin44$58,356
RybelsusSemaglutide21$49,119
XareltoRivaroxaban21$24,812
TrulicityDulaglutide14$13,435
TrintellixVortioxetine Hydrobromide12$10,774
Repatha SureclickEvolocumab15$8,476
Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf)11$6,382
SymbicortBudesonide/Formoterol Fumarate19$6,363
VyvanseLisdexamfetamine Dimesylate15$5,608
Atorvastatin Calcium399$3,732
Rosuvastatin Calcium245$3,561
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide129$3,560

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$3,659$312,226262 claims
Lilly USA, LLCMounjaro, Trulicity$151$292,013262 claims
PfizerEliquis$34$71,74665 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$11$16,38227 claims
AstraZenecaSymbicort$11$6,36319 claims
AbbVieSynthroid$45$2,18429 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →